FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3020004539> ?p ?o ?g. }

• W3020004539 abstract "Abstract Background The Global Programme to Eliminate Lymphatic Filariasis is making considerable progress but has experienced challenges in meeting targets in some countries. Recent World Health Organization guidelines have recommended two rounds of triple-drug therapy with ivermectin, diethylcarbamazine (DEC), and albendazole (IDA), in areas where mass drug administration (MDA) results with two drugs (DEC and albendazole) have been suboptimal, as is the case in Samoa. In August 2018, Samoa was the first in the world to implement countrywide triple-drug MDA. This paper aims to describe Samoa’s experience with program coverage and adverse events (AEs) in the first round of triple-drug MDA. Methodology/Principal findings We assessed MDA awareness, reach, compliance, coverage and AEs from three different data sources: a Supervisor’s Coverage Tool (SCT) in three villages; a large cross-sectional community survey in September/October 2018, 7-11 weeks after the first round of triple-drug MDA; and AE surveillance conducted by the Ministry of Health, Samoa. Participants aged ≥5 years had a fingerprick blood sample tested for circulating filarial antigen using the Alere Filariasis Test Strip. Data were analysed descriptively. In our sample of 4420 people (2.2% of the population), age-adjusted estimates indicated that 89.0% of the eligible population were offered MDA and 80.2% of the total population took MDA. Mild AEs were reported by 13.3% and moderate/severe AEs by 2.9% of participants. Conclusions/Significance This study following the 2018 triple-drug MDA in Samoa demonstrated a high reported program awareness and reach of 90.8% and 89.0%, respectively. Coverage of 80.2% of the total population showed that MDA was well accepted and well tolerated by the community. Author summary Lymphatic filariasis is a mosquito transmitted worm disease. A global program underway aims to eliminate lymphatic filariasis as a public health problem by distributing deworming drugs to the whole population once a year for at least five years. In some countries, including Samoa, this strategy has not been sufficient to eliminate transmission. A new drug has been added, and in 2018, Samoa was the first country in the world to apply triple drug mass drug administration using ivermectin, diethylcarbamazine, and albendazole. This study reports on the coverage achieved (percentage of people who reported taking the drugs) and adverse events after taking the drugs. Data were obtained from three different sources. A large community survey of over 4000 people, done 7-11 weeks after the distribution of the first round, found that the program reached and offered MDA to approximately 90% of the whole population, and approximately 80% of the whole population swallowed the drugs. Findings from the community survey on participation in the MDA program were consistent with those from the WHO recommended Supervisor’s Coverage Tool, a smaller survey which was undertaken in three villages by the Samoan Ministry of Health. Data on AEs related to MDA were collected during the community survey, and also through a system set up by the Ministry of Health to enable community members to report any problems related to MDA and receive advice on managing problems. There were relatively few adverse events reported and most of them were mild and of short duration." @default.
• W3020004539 created "2020-05-01" @default.
• W3020004539 creator A5017856805 @default.
• W3020004539 creator A5031352764 @default.
• W3020004539 creator A5034599786 @default.
• W3020004539 creator A5048486467 @default.
• W3020004539 creator A5054857534 @default.
• W3020004539 creator A5061008460 @default.
• W3020004539 creator A5068058892 @default.
• W3020004539 creator A5068862569 @default.
• W3020004539 creator A5073966797 @default.
• W3020004539 date "2020-04-24" @default.
• W3020004539 modified "2023-09-27" @default.
• W3020004539 title "An assessment of coverage and adverse events following country-wide triple-therapy mass drug administration for lymphatic filariasis elimination, Samoa 2018" @default.
• W3020004539 cites W2007516286 @default.
• W3020004539 cites W2028785633 @default.
• W3020004539 cites W2070407880 @default.
• W3020004539 cites W2092022025 @default.
• W3020004539 cites W2126641491 @default.
• W3020004539 cites W2181101964 @default.
• W3020004539 cites W2571540049 @default.
• W3020004539 cites W2743045386 @default.
• W3020004539 cites W2794366486 @default.
• W3020004539 cites W2803353483 @default.
• W3020004539 cites W2899911624 @default.
• W3020004539 cites W2946771710 @default.
• W3020004539 cites W2951495492 @default.
• W3020004539 doi "https://doi.org/10.1101/2020.04.21.20072363" @default.
• W3020004539 hasPublicationYear "2020" @default.
• W3020004539 type Work @default.
• W3020004539 sameAs 3020004539 @default.
• W3020004539 citedByCount "1" @default.
• W3020004539 countsByYear W30200045392020 @default.
• W3020004539 crossrefType "posted-content" @default.
• W3020004539 hasAuthorship W3020004539A5017856805 @default.
• W3020004539 hasAuthorship W3020004539A5031352764 @default.
• W3020004539 hasAuthorship W3020004539A5034599786 @default.
• W3020004539 hasAuthorship W3020004539A5048486467 @default.
• W3020004539 hasAuthorship W3020004539A5054857534 @default.
• W3020004539 hasAuthorship W3020004539A5061008460 @default.
• W3020004539 hasAuthorship W3020004539A5068058892 @default.
• W3020004539 hasAuthorship W3020004539A5068862569 @default.
• W3020004539 hasAuthorship W3020004539A5073966797 @default.
• W3020004539 hasBestOaLocation W30200045391 @default.
• W3020004539 hasConcept C141071460 @default.
• W3020004539 hasConcept C165901193 @default.
• W3020004539 hasConcept C203014093 @default.
• W3020004539 hasConcept C2776158911 @default.
• W3020004539 hasConcept C2777065887 @default.
• W3020004539 hasConcept C2777411658 @default.
• W3020004539 hasConcept C2777499811 @default.
• W3020004539 hasConcept C2777629521 @default.
• W3020004539 hasConcept C2780133432 @default.
• W3020004539 hasConcept C2908647359 @default.
• W3020004539 hasConcept C42972112 @default.
• W3020004539 hasConcept C71924100 @default.
• W3020004539 hasConcept C99454951 @default.
• W3020004539 hasConceptScore W3020004539C141071460 @default.
• W3020004539 hasConceptScore W3020004539C165901193 @default.
• W3020004539 hasConceptScore W3020004539C203014093 @default.
• W3020004539 hasConceptScore W3020004539C2776158911 @default.
• W3020004539 hasConceptScore W3020004539C2777065887 @default.
• W3020004539 hasConceptScore W3020004539C2777411658 @default.
• W3020004539 hasConceptScore W3020004539C2777499811 @default.
• W3020004539 hasConceptScore W3020004539C2777629521 @default.
• W3020004539 hasConceptScore W3020004539C2780133432 @default.
• W3020004539 hasConceptScore W3020004539C2908647359 @default.
• W3020004539 hasConceptScore W3020004539C42972112 @default.
• W3020004539 hasConceptScore W3020004539C71924100 @default.
• W3020004539 hasConceptScore W3020004539C99454951 @default.
• W3020004539 hasLocation W30200045391 @default.
• W3020004539 hasLocation W30200045392 @default.
• W3020004539 hasOpenAccess W3020004539 @default.
• W3020004539 hasPrimaryLocation W30200045391 @default.
• W3020004539 hasRelatedWork W17295794 @default.
• W3020004539 hasRelatedWork W20892562 @default.
• W3020004539 hasRelatedWork W20922700 @default.
• W3020004539 hasRelatedWork W223849 @default.
• W3020004539 hasRelatedWork W2786728 @default.
• W3020004539 hasRelatedWork W3144720 @default.
• W3020004539 hasRelatedWork W723089 @default.
• W3020004539 hasRelatedWork W7515770 @default.
• W3020004539 hasRelatedWork W14560034 @default.
• W3020004539 hasRelatedWork W8318334 @default.
• W3020004539 isParatext "false" @default.
• W3020004539 isRetracted "false" @default.
• W3020004539 magId "3020004539" @default.
• W3020004539 workType "article" @default.